How Would You Treat This Patient Hospitalized With Community-Acquired Pneumonia? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Zahir KanjeeJoshua P MetlayAri MoskowitzEileen E ReynoldsPublished in: Annals of internal medicine (2021)
Community-acquired pneumonia is a major cause of morbidity and mortality in the United States, leading to 1.5 million hospitalizations and at least 200 000 deaths annually. The 2019 American Thoracic Society/Infectious Diseases Society of America clinical practice guideline on diagnosis and treatment of adults with community-acquired pneumonia provides an evidence-based overview of this common illness. Here, 2 experts, a general internist who served as the co-primary author of the guidelines and a pulmonary and critical care physician, debate the management of a patient hospitalized with community-acquired pneumonia. They discuss disease severity stratification methods, whether to use adjunctive corticosteroids, and when to prescribe empirical treatment for multidrug-resistant organisms such as methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa .
Keyphrases
- community acquired pneumonia
- methicillin resistant staphylococcus aureus
- infectious diseases
- multidrug resistant
- pseudomonas aeruginosa
- case report
- gram negative
- staphylococcus aureus
- primary care
- acinetobacter baumannii
- cystic fibrosis
- spinal cord
- drug resistant
- clinical practice
- spinal cord injury
- combination therapy
- klebsiella pneumoniae